AXGN at a glance
Axogen, Inc. (AXGN, SEC CIK 805928) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as September 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Axogen, Inc. (AXGN) reported revenue of $225.2 million (up 20.2% from FY2024) and a net loss of $15.7 million. Diluted EPS was -$0.34.
- As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Axogen, Inc. (AXGN) shares worth $660.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by TYNDALL JOSEPH A. on September 2, 2026 of 3,500 shares at $49.70 per share.
- In the last 90 days, AXGN insiders reported 0 open-market purchases ($0) and 1 open-market sale ($174K) on Form 4, a net sale of $174K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $225.2M
- +20.2% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$174K
- 13F holders
- 30 funds
- $660.7M · −2 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Development and commercialization of innovative peripheral nerve regeneration and repair technologies
- New product: FDA-approved Avance® acellular nerve scaffold (December 3, 2025), launching Q2 2026, replacing Avance® Nerve Graft
- Strategic shift: Transition of Avance Products from Section 361 human tissue to licensed biologic under Section 351 with post-marketing study commitments
- Quantitative highlight: Avance Nerve Graft with 17+ years clinical use and over 120,000 implants, US peripheral nerve injury TAM estimated at >$5.6 billion
- Noteworthy fact: Launch of Avive+ Soft Tissue Matrix in June 2024, an amniotic membrane allograft under FDA HCT/P regulations subject to future oversight changes
Risk Factors
- Regulatory risk: FDA accelerated approval of Avance Products contingent on confirmatory trials with milestones through 2031; failure may cause withdrawal or restrictions
- Operational risk: Avance manufacturing relies on variable donated cadaveric tissue, causing potential lot failures, product recalls, and supply shortages
- Geopolitical/macroeconomic risk: Healthcare reimbursement uncertainty; CMS reimbursement changes in 2026 increased outpatient nerve repair payments by 96%-221%, impacting commercial payor coverage
- Competitive risk: Market acceptance dependent on overcoming surgeon concerns of allograft disease transmission and competing surgical techniques
- Financial risk: Dependence on six products, with Avance generating ~60% revenue; disruption in Avance sales could materially impact financials
Management Discussion & Analysis
- Revenue $225.2M, up 20.2% YoY from $187.3M driven by unit volume, price, and product mix changes
- Gross margin 74.3% vs 75.8% YoY, gross profit $167.4M up 17.9% from $142.0M, impacted by $1.9M one-time FDA BLA costs
- Sales & marketing best performer: $97.7M (+24.6%), R&D $32.9M (+18.4%), G&A $44.6M (+14.2%)
- Cash, cash equivalents, restricted cash, and investments $45.5M up $6.0M YoY; $133.3M net proceeds from Jan 2026 equity raise, $69.7M used to repay term loan
- 2026 outlook positive: new Level 3 nerve procedure code boosts reimbursement 35-40%, expanded insurance coverage to 19.8M lives, FDA approval dependency noted as key risk
AI summary of the AXGN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added merger-integration risk: BioCircuit acquisition may create costly, time-consuming integration challenges
- Operational risk: Management distraction and integration disruptions could impair existing operations
- Financial risk: Failure to realize anticipated Merger benefits could adversely affect financial condition and results of operations
Management Discussion & Analysis
- Q3 revenue $75,834, up $15,752 or 26.2% YoY, driven by higher unit volume and pricing
- Gross margin 74.8% vs 76.6% YoY, pressured by higher product costs
- Q3 net income $2,334, or 3.1% margin, vs $720, or 1.2% YoY
- Cash, equivalents and investments $348,068, up from $41,528; nine-month operating cash flow $25,322 vs $(2,226)
- $225,029 offering proceeds, $200,000 allocated to BioCircuit acquisition; trade disputes and macroeconomic instability potential headwinds
AI summary of the AXGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Axogen posted a corporate presentation on November 9, 2026 for use in analyst and investor discussions
- Presentation available through Axogen’s investor-relations website and Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Corporate presentation outlines a prostate nerve reconstruction launch using Avance, expanding Axogen beyond its existing peripheral-nerve markets
- Estimated addressable market: approximately 110,000 annual cases and $754 million TAM at approximately $7,000 weighted ASP
Item EX-99.2: Item EX-99.2
- Q3 revenue $75.8M, up 26.2% YoY, extending strong growth across Axogen’s nerve-care markets
- Adjusted EBITDA $13.4M, margin 17.7% versus 15.4%, signaling operating leverage despite expanded commercial investment
Item EX-99.1: Item EX-99.1
- Q3 revenue $75.8M, up 26.2% YoY, with broad-based growth across major markets
- Adjusted EBITDA $13.4M, up from $9.2M, while gross margin declined to 74.8% from 76.6%
Item EX-99.3: Item EX-99.3
- Corporate presentation outlines a $5.6B U.S. nerve-care opportunity, with minimal current penetration and more than 1.5M annual injuries in focus markets
- 2026 guidance: revenue growth at least 29% to $290M, organic growth at least 26% to $283M, gross margin at least 73%, positive free cash flow
Item 2.02: Results of Operations and Financial Condition
- Axogen announced third-quarter 2026 financial results on October 28, 2026
- Full financial results and management commentary are contained in Exhibit 99.1, the accompanying earnings release
Item 7.01: Regulation FD Disclosure
- Q3 2026 financial results presentation posted October 28, 2026, providing investor-facing performance information
- Updated corporate presentation posted October 28, 2026, signaling refreshed company strategy and business overview
Item 7.01: Regulation FD Disclosure
- Axogen completed its previously announced acquisition of BioCircuit Technologies on October 1, 2026
- Transaction expands Axogen’s portfolio through BioCircuit Technologies, with strategic and integration implications
Item EX-99.1: Item EX-99.1
- Acquisition of BioCircuit Technologies completed, adding NerveTape™, the first FDA-cleared sutureless peripheral nerve repair device
- BioCircuit expected to contribute approximately $6 million revenue in fourth-quarter 2026 and $34 million in 2027
AI summaries of AXGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AXGN
Don't miss the next AXGN filing
- Alerts as it files. A push when AXGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AXGN, by share count.
- Ask anything. An AI agent that reads every AXGN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| TYNDALL JOSEPH A. | Sell | Sep 2, 2026 | 3,500 | $49.70 |
| Wendell Amy McBride | M | Aug 11, 2026 | 13,353 | $14.85 |
| Wendell Amy McBride | Sell | Aug 11, 2026 | 13,353 | $48.42 |
| Wendell Amy McBride | M | Aug 11, 2026 | 13,353 | - |
| Began Marc A | Sell | Aug 10, 2026 | 67,500 | $47.34 |
| Began Marc A | M | Aug 10, 2026 | 67,500 | - |
| Began Marc A | M | Aug 10, 2026 | 67,500 | $8.16 |
| Weiler Kathy Johnson | Sell | Aug 7, 2026 | 14,150 | $45.30 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $187.3M | $225.2M |
| Gross Profit | - | $142.0M | $167.4M |
| Operating Income | - | -$3.3M | -$7.8M |
| Net Income | - | -$10.0M | -$15.7M |
| Gross Margin | - | 75.8% | 74.3% |
| Op. Margin | - | -1.8% | -3.5% |
| Net Margin | - | -5.3% | -7.0% |
| Balance Sheet | |||
| Total Assets | $196.8M | $203.7M | $221.7M |
| Equity | $95.7M | $103.9M | $128.8M |
| ROE | - | -9.6% | -12.2% |
| Per Share | |||
| EPS | - | $-0.23 | $-0.34 |
| Cash Flow | |||
| Operating CF | - | $4.5M | $812K |
| CapEx | - | $3.1M | $3.7M |
Source: XBRL data in Axogen, Inc. (AXGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AXGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 30 | $660.7M |
| Q2 2026 | 32 | $890.0M |
| Q1 2026 | 29 | $569.9M |
| Q4 2025 | 25 | $494.1M |
| Q3 2025 | 26 | $241.0M |
| Q2 2025 | 28 | $151.3M |
| Q1 2025 | 27 | $205.1M |
| Q4 2024 | 22 | $112.6M |
- T. Rowe Price Group+217.5K (+21%)
- Vanguard Capital Management LLC+175.6K (+8%)
- BlackRock+161.2K (+4%)
- Dimensional Fund Advisors+127.7K (+31%)
- Millennium Management+127.2K (+467%)
- Citadel Advisors LLC−1.33M (-98%)
- Morgan Stanley−957.8K (-35%)
- Goldman Sachs Group−515.3K (-41%)
- Two Sigma Investments−227.3K (-71%)
- D.E. Shaw & Co−189.2K (-68%)
- FMR LLC (Fidelity)−1.22M
- Blackstone Group−15.5K
- Mangrove Partners−5.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 219 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AXGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Oct 28, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
Related Health Care companies
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
AXGN SEC filings: frequently asked questions
Are AXGN insiders buying or selling?
In the last 90 days, Axogen, Inc. (AXGN) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $173,940 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AXGN stock?
As of September 30, 2026, the largest Axogen, Inc. (AXGN) holders among the 13F filers tracked by SignalX were BlackRock ($192.0 million), Vanguard Capital Management LLC ($102.0 million), Morgan Stanley ($75.0 million), State Street Corp ($53.7 million), T. Rowe Price Group ($51.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AXGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Axogen, Inc. (AXGN) reported revenue of $225.2 million (up 20.2% from FY2024) and a net loss of $15.7 million. Diluted EPS was -$0.34. The figures come from the XBRL data in the 10-K.
What are the main risks in AXGN's latest 10-K?
In the 10-K filed February 24, 2026, Axogen, Inc. (AXGN) flagged: Regulatory risk: FDA accelerated approval of Avance Products contingent on confirmatory trials with milestones through 2031; failure may cause withdrawal or restrictions. Operational risk: Avance manufacturing relies on variable donated cadaveric tissue, causing potential lot failures, product recalls, and supply shortages. (AI summary of the Risk Factors section.)
What did AXGN report in its latest 8-K?
Axogen, Inc. (AXGN) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure). Axogen posted a corporate presentation on November 9, 2026 for use in analyst and investor discussions.
What are the latest AXGN SEC filings?
Axogen, Inc. (AXGN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on September 4, 2026.
What is AXGN's SEC CIK number?
Axogen, Inc. (AXGN)'s SEC Central Index Key (CIK) is 805928. EDGAR lists every AXGN filing under that number.
Ask anything about AXGN
The research agent reads AXGN's filings, financials, insider trades and 13F holders, then answers with sources.